These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 36812760)

  • 1. Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer.
    Auclin E; Benitez-Montanez J; Tagliamento M; Parisi F; Gorria T; Garcia-Campelo R; Dempsey N; Pinato DJ; Reyes R; Albarrán-Artahona V; Dall'Olio F; Soldato D; Hendriks L; Nana FA; Tonneau M; Lopez-Castro R; Nadal E; Kazandjian S; Muanza T; Blanc-Durand F; Fabre E; Castro N; Arasanz H; Rochand A; Besse B; Routy B; Mezquita L
    Lung Cancer; 2023 Apr; 178():116-122. PubMed ID: 36812760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of first-line treatments in metastatic squamous non-small-cell lung cancer.
    Levy BP; Signorovitch JE; Yang H; Patterson-Lomba O; Xiang CQ; Parisi M
    Curr Oncol; 2019 Jun; 26(3):e300-e308. PubMed ID: 31285672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.
    Lee K; Bang K; Yoo C; Hwang I; Jeong JH; Chang HM; Oh D; Song TJ; Park DH; Lee SS; Lee SK; Kim MH; Park JH; Kim KP; Ryoo BY
    Cancer Res Treat; 2020 Jan; 52(1):254-262. PubMed ID: 31291709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50.
    Attili I; Valenza C; Santoro C; Antonarelli G; Trillo Aliaga P; Del Signore E; Catania C; Spitaleri G; Passaro A; de Marinis F
    Front Oncol; 2022; 12():980765. PubMed ID: 36033444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the efficacy and safety of nivolumab in the second- or later-line treatment of patients with locally advanced/metastatic non-small cell lung cancer in Türkiye: a retrospective multicenter non-interventional registry study.
    Karadurmus N; Kaplan MA; Sendur MAN; Urun Y; Demirci U; Karaca SB; Goktas Aydin S; Aykan MB; Bilici A; Sezer A; Yilmaz U; Abali H; Yumuk PF; Degirmencioglu S; Demirkazik A; Paydas S; Mirili C; Turna H; Kargi A; Ozdogan M; Guven DC; Ozguroglu M; Kilickap S
    Curr Med Res Opin; 2024 Jul; 40(7):1171-1178. PubMed ID: 38809230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Real-World Data Study to Evaluate Treatment Patterns, Clinical Characteristics and Survival Outcomes for First- and Second-Line Treatment in Locally Advanced and Metastatic Urothelial Cancer Patients in Germany.
    Niegisch G; Gerullis H; Lin SW; Pavlova J; Gondos A; Rudolph A; Haas G; Hennies N; Kramer MW
    J Cancer; 2018; 9(8):1337-1348. PubMed ID: 29721042
    [No Abstract]   [Full Text] [Related]  

  • 7. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in Extensive-Stage small cell lung cancer (ES-SCLC) patients: A large French multicenter study.
    Pons-Tostivint E; Ezzedine R; Goronflot T; Crequit P; Chatellier T; Raimbourg J; Bennouna J; Giroux Leprieur E; Porte M
    Lung Cancer; 2024 Jul; 194():107887. PubMed ID: 38991282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment patterns and outcomes among patients with small-cell lung cancer (SCLC) in Europe: a retrospective cohort study.
    Blackhall F; Girard N; Livartowski A; McDonald L; Roset M; Lara N; Juarez García A
    BMJ Open; 2023 Feb; 13(2):e052556. PubMed ID: 36746549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP).
    Ruiz-Patiño A; Arrieta O; Cardona AF; Martín C; Raez LE; Zatarain-Barrón ZL; Barrón F; Ricaurte L; Bravo-Garzón MA; Mas L; Corrales L; Rojas L; Lupinacci L; Perazzo F; Bas C; Carranza O; Puparelli C; Rizzo M; Ruiz R; Rolfo C; Archila P; Rodríguez J; Sotelo C; Vargas C; Carranza H; Otero J; Pino LE; Ortíz C; Laguado P; Rosell R;
    Thorac Cancer; 2020 Feb; 11(2):353-361. PubMed ID: 31828967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Patterns and Clinical Outcomes Among Metastatic Non-Small-Cell Lung Cancer Patients Treated in the Community Practice Setting.
    Nadler E; Espirito JL; Pavilack M; Boyd M; Vergara-Silva A; Fernandes A
    Clin Lung Cancer; 2018 Jul; 19(4):360-370. PubMed ID: 29576407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer.
    Waterhouse D; Lam J; Betts KA; Yin L; Gao S; Yuan Y; Hartman J; Rao S; Lubinga S; Stenehjem D
    Lung Cancer; 2021 Jun; 156():41-49. PubMed ID: 33894493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health outcomes and healthcare resource utilization among Veterans with stage IV non-small cell lung cancer treated with second-line chemotherapy versus immunotherapy.
    Williams CD; Allo MA; Gu L; Vashistha V; Press A; Kelley M
    PLoS One; 2023; 18(2):e0282020. PubMed ID: 36809528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study).
    Nakamura A; Yamaguchi O; Mori K; Miura K; Tamiya M; Oba T; Yanagitani N; Mizutani H; Ninomiya T; Kajiwara T; Ito K; Miyanaga A; Arai D; Kodama H; Kobayashi K; Kaira K
    Eur J Cancer; 2023 May; 184():62-72. PubMed ID: 36905770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data.
    Pérol M; Felip E; Dafni U; Polito L; Pal N; Tsourti Z; Ton TGN; Merritt D; Morris S; Stahel R; Peters S
    Ann Oncol; 2022 May; 33(5):511-521. PubMed ID: 35218887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy.
    Reck M; Syrigos K; Miliauskas S; Zöchbauer-Müller S; Fischer JR; Buchner H; Kitzing T; Kaiser R; Radonjic D; Kerr K
    Lung Cancer; 2020 Oct; 148():159-165. PubMed ID: 32927350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer.
    Elkrief A; Riccuiti B; Alessi JV; Fei T; Kalvin HL; Egger JV; Rizvi H; Thummalapalli R; Lamberti G; Plodkowski A; Hellmann MD; Kris MG; Arcila ME; Baine MK; Rudin CM; Lito P; Ladanyi M; Schoenfeld AJ; Riely GJ; Awad MM; Arbour KC
    Oncologist; 2023 Nov; 28(11):978-985. PubMed ID: 37589215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program.
    Corral J; Majem M; Rodríguez-Abreu D; Carcereny E; Cortes ÁA; Llorente M; López Picazo JM; García Y; Domine M; López Criado MP
    Clin Transl Oncol; 2019 Sep; 21(9):1270-1279. PubMed ID: 30771085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy.
    Lefebvre C; Martin E; Hendriks LEL; Veillon R; Puisset F; Mezquita L; Ferrara R; Sabatier M; Filleron T; Dingemans AC; Besse B; Raherisson C; Mazières J
    Respir Med Res; 2020 Nov; 78():100788. PubMed ID: 32980653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.